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and Jørgen Erik Nielsen4,5Abstract
Background: Adrenomyeloneuropathy (AMN) is one of several phenotypes of the adrenoleukodystrophy spectrum
caused by mutations in the ABCD1 gene on the X chromosome. An inflammatory component is part of the disease
complex ranging from severe childhood CNS demyelination to spinal cord and peripheral nerve degeneration.
Case presentation: We present a patient with clinical progressive AMN and severe lower limb pain. Longitudinal
brain magnetic resonance spectroscopy showed a constant slightly elevated myoinositol/total creatine ratio during
the five year treatment period, probably reflecting demyelination, microglial activation and gliosis, indicating an
inflammatory response. The pain was refractory to conventional therapy but intravenous immunoglobulin (IVIG)
treatment was highly efficient.
Conclusion: IVIG may be considered as a last resort for treatment of refractory pain in AMN patients with
indications of an inflammatory component.
Keywords: Adrenomyeloneuropathy, Limb pain, IVIG treatment, Magnetic resonance spectroscopyBackground
Adrenomyeloneuropathy (AMN) is the adult form of the
progressive neurodegenerative condition, X-linked adre-
noleukodystrophy. Mutations in the ABCD1 gene result
in a disrupted peroxisomal beta oxidation causing accu-
mulation of the saturated very long chain fatty acids.
The AMN phenotype is found in approximately 45% of
the male patients with ABCD1 mutations [1]. AMN pre-
sents in adult age with slowly progressive spastic para-
plegia, sphincter disturbances, sensory disturbances,
ataxia, pain and impotence [2]. AMN patients with the
cerebral phenotype develop a cerebral inflammatory in-
volvement with a faster progression, whereas patients
with “pure” AMN can present with a mild inflammatory
response mainly limited to the spinal cord and periph-
eral nerves [2,3].
We describe a patient with AMN who was treated
successfully for severe leg pain with intravenous im-
munoglobulin (IVIG). During five years of treatment
the disease progressed; however, magnetic resonance* Correspondence: aia@kennedy.dk
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reproduction in any medium, provided the orspectroscopy (MRS) revealed a stable, mildly elevated
myoinositol (mI)/total creatine (Cr) ratio.Case presentation
A 48 year old Caucasian man was referred because of
progressing pain, numbness, and stiffness of his lower
limbs during 3-4 years. Lower urinary tract symptoms
were absent. Neurological examination revealed hyper-
active tendon reflexes in both arms and legs and bilateral
Babinski reflexes. Except from a slightly increased tone
distally in his legs he had an overall normal muscle tone
and no limb weaknesses. The only abnormal sensory
finding was an impaired sense of vibration in his first
toes. He developed erectile dysfunction and reduced
libido at 49 years of age. It was treated with sildenafil,
tadalafil and later testosteronundecanoat with almost no
effect.
Neurological examination at 55 years of age revealed a
moderate lower limb spastic paraplegia, hyperactive deep
tendon reflexes in both arms and legs, Babinski’s sign bi-
laterally, distally impaired thermal sensation and
decreased sense of vibration distally of the knees, con-
firming clinical progression during the seven years.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blood biochemistry, including vitamin B12 concentra-
tion, methylmalonic acid, glycosylated hemoglobin,
HTLV1 and HTLV2 (Human T-cell Lymphotropic
Viruses), p-ANCA and c-ANCA (Anti-Neutrophil Cyto-
plasmic Antibodies), ANA (Anti-Nuclear Antibodies),
HIV, syphilis, and arylsulfatase A activity. Cerebrospinal
fluid analysis showed an increased spinal protein level of
0.78 g/l (normal 0.15-0.50 g/l), absent oligoclonal bands,
and no Borrelia Burgdorferi antibodies.
Electrophysiological studies including EMG (electro-
myography), ENG (electroneurography), SSEP (somato-
sensory evoked potentials), and VEP (visual evoked
potentials) were normal. MEP (motor evoked potentials)
showed increased central conduction time (CCT) to
muscles in the upper and lower extremities. The muscles
investigated were biceps brachii (BB), flexor carpi radial
is (FCR), first dorsal interosseus (FDI), tibialis anterior
(TA), and abductor hallucis (AH). The CCT was
increased by 45% and 34% to the right and left FCR, re-
spectively. The CCT to the right side FDI was increased
by 22% and the left side was normal. The CCT to TA
was increased by 25% and 56% and to AH by 26% and
30% to right and left side, respectively. The CCT to both
BB was normal. Peripheral conduction time was
increased by 20% and 23% to right and left TA, respect-
ively, and also to the right AH with 18%. The peripheral
conduction times to BB, FCR and FDI were all normal.
The profile of saturated very long chain fatty acid
(VLCFA) of serum was diagnostic of AMN, showing a
ratio between C24 and C22 of 146% (normal 40-105%)
and a ratio between C26 and C22 of 6.0% (normal 0-3%).
The AMN diagnosis was confirmed by identification
of a novel c.2005C>T mutation in the ABCD1 gene
(Reference sequence: NM00033.3) predicting an amino
acid shift from histidine to tyrosine at position 669
p. His669Tyr.Figure 1 Brain Magnetic Resonance Spectroscopy. Short echo time ma
occipito-parietal primarily white matter and from mid-occipital primarily grAn ACTH stimulation test showed no adrenal insuffi-
ciency, but testosterone was slightly decreased (9.2 to
13 nmol/l; normal 10.0-28 nmol/l).
Repeated MRI’s (magnetic resonance imaging) of the
brain and spinal cord during five years were normal.
Short echo time MRS (magnetic resonance spectros-
copy) studies were performed at ages 49, 50, 51, 53,
and 55 years. The ratios of N-acetylaspartate (NAA),
total choline (Cho), and mI to total Cr were calculated
and results deviating more than 2 standard deviations
(SD) from normal were regarded as abnormal. MRS
showed elevated mI/Cr. The mI/Cr ratios were stable
over time and on average 27% increased compared to
the normal controls during the six years of study. The
NAA/Cr ratios were low in the normal range or
decreased to just below the normal range, but the
NAA/Cr ratios did not change significantly over time.
The Cho/Cr ratio stayed in the normal range all six
years of study (Figure 1).
The patient had increasing pain from his legs during
the years. The pain was described as initially a pricking
and tingling sensation but later a constant, night and
day, burning, stabbing pain, which was not precipitated
by contact, temperature or movements.
The pain in his lower limbs was initially treated with
peripheral analgesics, which had no effect. Later tizani-
din, levodopa, amitriptylin, oxacarbazepin, and pregaba-
lin were tried but all resulting in unacceptable side
effects with no benefit.
Based on the involvement of an immune/inflammatory
process in the pathogenesis of ALD/AMN, the increased
CSF protein and the MRS data, immunosuppressive
therapy with IVIG was initiated as a last resort. Treat-
ment with IVIG was initialized in an in-house standard
scheme of 30 g IVIG a day for three consecutive days
every third month when the patient was 49 years old.
Trying to increase the interval between treatments wasgnetic resonance spectra acquired at three Tesla from left and right
ey matter in the patient at age 52 years.
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treatment was continued during five years approximately
every third month and was administered when the
symptoms deteriorated with increasing pain. The treat-
ment led to clear improvement, reducing his pain from
9 to 3 on a “visual analogue scale” of 10.
Discussion
Here we report on an AMN patient with a progressive
spastic paraplegia, erectile dysfunction and severe pain
in the lower limbs refractory to conventional treatment.
A small fiber neuropathy may be the underlying cause of
the pain but unfortunately the electrophysiological
investigations aimed at revealing large fiber neuropathy
and the patient was reluctant to participate in further
electrophysiological investigations, skin biopsy or sural
nerve biopsy. MRI of the brain was normal; however,
cerebral involvement was revealed by MRS showing ele-
vated mI/Cr. This finding probably reflects demyelin-
ation, microglial activation and gliosis, indicating a
possible inflammatory component.
Spectroscopic evidence of biochemical abnormalities
in AMN has previously been reported. Reduction of
both NAA/Cho and NAA/Cr were found most severely
in the internal capsule and parieto-occipital white mat-
ter, whereas no significant elevation of Cho/Cr was
found. These results were suggested to reflect axonal
damage in the brains of pure AMN patients [4]; how-
ever, the long echo time used in the study by Dubey
and colleagues (2005), did not allow detection of mI
and consequently a possible inflammatory component.
Twenty percent of the “pure” AMN patients develop
the cerebral phenotype [3] and based on the MRS we
suggest classifying our patient as an inflammatory cere-
bral type AMN.
Currently, the most efficient therapeutic opportunity
for patients with the cerebral form of adrenoleukody-
strophy (ALD) is hematopoietic stem cell transplant-
ation, whereas applications of immunomodulatory and
immunosuppressive drugs have failed to prevent pro-
gression of cerebral neuroinflammation [5].
Heterogeneous peripheral and central mechanisms
are presumably involved in the pain related to AMN.
The exact pathophysiological mechanisms are un-
known, but might depend of antibodies to neuronal
structures as seen in neuropathy associated with dia-
betes [6]. Furthermore, cytokines and growth factors
have been suggested to play a role in initiating or
maintaining neuropathic pain [7]. IVIGs have different
actions, including modulation of pathogenic autoanti-
bodies and inhibition of complement activation and
cytokines [8], which might be related to the beneficial
effect in our patient. IVIG was previously reported to
reduce neuropathic pain associated with Sjögren'ssyndrome, an autoimmune disease, and to reduce pain
and improve motor function markedly in proximal dia-
betic neuropathy [9,10].
IVIG treatment has hitherto not been reported in
AMN but previously administered to ALD patients with-
out clear effect on disease progression and it is presently
not a recommended treatment [5]. MRS revealed normal
Cho/Cr and the NAA/Cr ratios in our patient and those
ratios did not change significantly during the follow up
period. IVIG was highly effective in the pain treatment,
but whether the IVIG treatment influenced the disease
course, prevented axonal damage in the brain and stabi-
lized the mI/Cr remains speculative. The present study
should be interpreted with caution and IVIG is not
recommended for AMN in general; however, as a last re-
sort for treating otherwise refractory pain in AMN, IVIG
may be explored.
Conclusion
The patient with a novel c.2005C>T mutation in the
ABCD1 gene had an AMN phenotype with severe leg
pain. According to MRS, indicating a coexisting cerebral
demyelination and inflammation he was classified as
AMN cerebral phenotype. IVIG treatment relieved the
severe pain and it may be considered in otherwise
treatment-refractory pain of AMN, cerebral type.
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